Search for: "Mylan Pharmaceuticals"
Results 501 - 520
of 739
Sorted by Relevance
|
Sort by Date
8 Oct 2009, 6:05 am
Teva, Mylan, Dr. [read post]
13 Jan 2010, 3:00 am
Cobrek Pharmaceuticals, Inc (Patent Docs) Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb) Nuvigil (Armodafinil) - US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief) Nuvigil (Armodafinil) - US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle) Tasigna (Nilotinib) - India:… [read post]
23 Apr 2009, 10:00 pm
(Spicy IP) India: Assessing India’s innovation climate (Biotech Blog) Kenya’s anti-counterfeit legislation, India protest (Afro-IP) Mexico: Pharmaceutical trade marks: the Health Law pitfall for applicants (International Law Office) US: BIO IP Counsels’ Committee: Q Todd Dickinson and E Anthony Figg on patent reform (Patent Docs) US: Amgen VP makes case for longer exclusivity period in follow-on biologics legislation (Patent Docs) Products Cepham… [read post]
16 Dec 2009, 3:39 am
: Ariad Pharmaceuticals, Inc. v. [read post]
13 Oct 2014, 9:01 am
The Teva Pharmaceuticals case combines a core question about how the Federal Circuit reviews trial court decisions on the scope of patents, a new examination of a key 1996 Supreme Court precedent, an unrelenting battle among companies in the pharmaceutical business, and the right to control the sale of one of the most profitable medicines ever invented. [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
16 May 2012, 12:22 pm
Mylan Pharmaceuticals, Inc., ___ F. [read post]
22 May 2015, 10:38 am
Shortly afterwards, the injunction on Krka was lifted.The declaration of non-infringement awarded to Ranbaxy opened the door to the marketing of generic esomeprazole products by a series of other companies, including Arrow, Mylan and Teva. [read post]
7 May 2012, 5:00 am
Mylan Pharmaceuticals, Inc., ___ F. [read post]
7 Dec 2016, 11:58 pm
Mylan contended that not all forms of pain which fell within the claims contained a central sensitisation component. [read post]
28 Jul 2010, 12:06 am
(Patent Docs) Namenda (Memantine) – US: Mylan announces settlement agreement with Forest Lab’s and Merz Pharmaceuticals (SmartBrief) Olux-E (Clobetasol) – US: Patent infringement complaint following a Paragraph IV certification: Stiefel Laboratories Inc. et al. v. [read post]
8 Mar 2011, 7:54 am
Generic versions of Topamax, known generally as topiramate, are sold by Teva Pharmaceuticals, Watson Pharmaceuticals, and Mylan as well as other generic drug companies. [read post]
1 Dec 2010, 12:15 am
General Australia: Gene patents survive Australian Senate enquiry – for now (Patentology) China: Why China is preferred over India by the US pharmaceutical industry (IP Dragon) China: Parasiting trademarks of drugs in China breeds resistant malaria parasite (IP Dragon) EU guidelines clear way for biosimilar antibodies (GenericsWeb) EU: SPCs and the ‘salt’ problem no 2 (The SPC Blog) UK: Cephalon v Orchid – a path less clear? [read post]
15 Jan 2012, 6:57 am
It is distributed by Mylan Pharmaceuticals. [read post]
13 Nov 2012, 4:40 pm
The manufacturer is Mylan Pharmaceuticals.) [read post]
29 May 2024, 11:27 am
Mylan Pharmaceuticals Inc., Case No. 1:22-CV61 (KLEEH) (N.D. [read post]
1 Jul 2022, 10:02 am
Mylan Pharmaceuticals Inc., No. 21-1567, also focuses on the written description requirement – asking what level of disclosure is necessary for a claim limitation requiring a therapeutic treatment to be “effective. [read post]
28 Oct 2015, 5:17 am
” In a second post at Dubitante, Sadowsky discusses the petition in “an important prescription drug patent case involving similar issues, Mylan Pharmaceuticals vs. [read post]
14 Feb 2019, 7:05 am
Mylan Pharmaceuticals Inc. 18-899 Issue: Whether inter partes review before the Patent Trial and Appeal Board is the type of proceeding in which tribal sovereign immunity may be asserted. [read post]
